Selected national pharmacovigilance websites: An analysis of contents

Drug Safety

Volumn 35, Issue 2, 2012, Pages 141-148

  Barker, Charlotte I S ^a   Talbot, John C C ^b   Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Adverse drug reactions; Electronic information services; Pharmacovigilance

Indexed keywords

ARTICLE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH SURVEY; PRIORITY JOURNAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; HUMANS; INFORMATION STORAGE AND RETRIEVAL; INTERNET; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE;

EID: 84855847579     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11596270-000000000-00000     Document Type: Article

References (19)

1. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. WHO, 2002 [online]. Available from URL: http://apps.who.int/medicinedocs/en/d/Js4893e/[Accessed 2010 Sep 12]
2. The Uppsala Monitoring Centre [online]. Available from URL: http://www.who-umc.org/[Accessed 2010 Sep 12]
3. Greer T, Holinga D, Kindel C, et al. An educators' guide to credibility and web evaluation. Why evaluate web information. Revised 2002 Brown J, Hickey K, Pozen V; 2002 addendum Adreon H, Catey A, Strysick K. [online]. Available from URL: http://www.ed.uiuc.edu/wp/credibility/page2. html [Accessed 2010 Sep 12]
4. Kim P, Eng TR, Deering MJ, et al. Published criteria for evaluating health related web sites: review. BMJ 1999; 318 (7184): 647-9 (Pubitemid 29192059)
5. Westbye O, Dahlin A, Karlsson K, et al. Pharmaceuticals and the Internet: drug regulatory authorities' perspective. Nordic Council on Medicines (NLN) and the World Health Organization, 2001 [online]. Available from URL: http://apps.who.int/medicinedocs/pdf/h2960e/h2960e.pdf [Accessed 2010 Sep 12]
6. Vitry A, Lexchin J, Sasich L, et al. Provision of information on regulatory authorities' websites. Intern Med J 2008; 38 (7): 559-67
7. World Health Organization. Optimization of medicines regulatory authority web sites. WHO Drug Inf 2010; 24 (2): 91-8
8. Anton C, Cox AR, Coleman JJ, et al. A comparison of publicly available spontaneous adverse drug reaction data from national spontaneous reporting schemes [abstract]. Drug Saf 2006; 29 (10): 914
9. Uppsala Monitoring Centre. Address list of national centers that participate in the WHO drug monitoring programme. In: Aronson JK, editor. Side effects of drugs annual 30. Amsterdam: Elsevier, 2008: 582-95
10. Medicines and Healthcare products Regulatory Agency. Black triangle scheme [online]. Available from URL: http://www.mhra.gov.uk/Safetyinformation/ Reportingsafetypro blems/Reportingsuspectedadversedrugreactions/Healthcare professionalreporting/BlackTriangleScheme/[Accessed 2010 Sep 12]
11. Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32 (2): 99-110
12. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28 (10): 851-70 (Pubitemid 41428543)
13. The European Ombudsman. Draft recommendation of the European Ombudsman in his inquiry into complaint 2493/2008/(BB)TS against the European Medicines Agency [online]. Available from URL: http://www.ombudsman. europa.eu/cases/ draftrecommendation.faces/en/4810/html. bookmark [Accessed 2010 Oct 23]
14. Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2003/2004; 16: 5-19 (Pubitemid 37475764)
15. Aronson JK. Bottled lightning. BMJ 2005; 331: 824
16. Loke YK, Derry S, Price D, et al. Case reports of suspected adverse drug reactions: systematic literature survey of follow-up. BMJ 2006; 332: 335-9
17. Position of the European Parliament adopted at first reading on 22 September 2010 with a view to the adoption of Regulation (EU) No ./2010 of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (paragraph 15) [online]. Available from URL: http://www.europarl.europa.eu/ sides/get Doc.do?pubRef=-//EP//TEXT+TA+P7-TA-2010-0331+0 +DOC+XML+V0// EN&language=EN#BKMD-4 [Accessed 2010 Oct 23]
18. Health Canada. Biologics, radiopharmaceuticals and genetic therapies [online]. Available from URL: http://www.hc-sc.gc. ca/dhp-mps/brgtherap/index- eng.php [Accessed 2010 Sep 12]
19. Uppsala Monitoring Centre. The global intelligence network for benefits and risks in medicinal products [online]. Available from URL: http://www.who-umc.org/DynPage. aspx?id=13140&mn=1514 [Accessed 2010 Sep 12]